
Opinion|Videos|April 26, 2024
RCC: Treatment Goals in the Third-Line Setting
Focusing on VEGF TKIs available for the treatment of patients with metastatic renal cell carcinoma, the panel discusses the goals of therapy in the third-line setting.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Rezatapopt Shows 46% ORR in TP53 Y220C–Mutated Ovarian Cancer
2
Daraxonrasib Shows Antitumor Activity in RAS-Mutant NSCLC
3
G2032R Resistance Data Is Reshaping Second-Line Sequencing in ROS1+ NSCLC
4
First-Line Savolitinib/Osimertinib Improves PFS in MET+ NSCLC
5

































